See the DrugPatentWatch profile for alphagan
The generic name for Alphagan P 0.1 is brimonidine tartrate ophthalmic solution 0.1% [1].
When did the brand-name drug's patent expire?
The patent for Alphagan P expired in 2018, allowing for the introduction of generic versions [2].
Who makes generic brimonidine tartrate ophthalmic solution 0.1%?
Several pharmaceutical companies manufacture generic brimonidine tartrate ophthalmic solution 0.1%. These include Teva Pharmaceuticals, Allergan (which originally developed Alphagan P), and numerous other generic drug manufacturers [3].
How does generic brimonidine compare to Alphagan P?
Generic brimonidine tartrate ophthalmic solution 0.1% is bioequivalent to the brand-name Alphagan P 0.1%. This means it has the same active ingredient, dosage form, strength, and route of administration, and it is expected to produce the same clinical effect and safety profile [4].
What is brimonidine tartrate used for?
Brimonidine tartrate ophthalmic solution 0.1% is used to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [1]. Elevated IOP is a risk factor for vision loss from glaucoma.
What are the potential side effects of brimonidine tartrate?
Common side effects of brimonidine tartrate ophthalmic solution include eye redness, burning, stinging, or discomfort upon instillation. Some patients may also experience dry mouth, fatigue, or headache [5]. It is important for patients to discuss any side effects with their healthcare provider.
Can brimonidine tartrate cause serious side effects?
In rare cases, brimonidine tartrate can cause more serious side effects, such as a severe allergic reaction, very dry eyes, or vision changes. It can also be absorbed into the bloodstream and potentially cause symptoms like slow heart rate, dizziness, or drowsiness. Patients should seek medical attention if they experience any severe adverse reactions [5].
Where can I find more information on brimonidine tartrate patents?
Information regarding patents for brimonidine tartrate, including expiry dates and any related litigation, can be found on DrugPatentWatch.com [2].
---
Sources:
1. https://www.drugpatentwatch.com/drugs/brimonidine-tartrate-ophthalmic-solution-0-1
2. https://www.drugpatentwatch.com/blog/alphagan-p-patent-expiration
3. https://www.accessdata.fda.gov/scripts/drugRough/
4. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/ANDA-archive
5. https://www.rxlist.com/brimonidine-tartrate-ophthalmic-side-effects-drug-center.htm